Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 clinical trials to determine the frequency and retention of TVR-resistant variants in patients who did not achieve sustained virologic response (SVR).
Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 clinical trials to determine the frequency and retention of TVR-resistant variants in patients who did not achieve sustained virologic response (SVR).
Methods. A total of 1797 patients were treated with TVR. Resistant variants (V36A/G/I/L/M, T54A/S, I132V [subtype 1a only], R155G/K/T/M, A156F/N/S/T/V, and D168N) were identified after treatment failure and at visits thereafter, by direct ( population) sequencing of the NS3/4A region. Kaplan-Meier analysis was used to determine median time to loss of these variants.
Results. Resistant variants were observed in 77% (299/388) of patients who did not achieve SVR. Resistance occurred more commonly in subtype 1a (86%; 232/269) than subtype 1b infections (56%; 67/119). After treatment failure, 355 patients had at least 1 follow-up visit (median follow-up period: 9.6 months). Of patients with resistance at time of failure and at least 1 follow-up visit, 60% (153/254) lost resistance. Kaplan-Meier analysis, including all patients with any sequence data after treatment failure, indicated that median time to wild type was 10.6 months (95% confidence interval [CI], 9.47-12.20) in subtype 1a and 0.9 months (95% CI, 0.00-2.07) in subtype 1b infections.
Conclusions. After failure to achieve SVR with TVR-based treatment, resistant variants are observed in most patients. However, presumably due to the lower fitness of those variants, they tend to be replaced with wild-type virus over time.
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The introduction of the first direct-acting antiviral agents has changed the paradigm for treatment of hepatitis C virus (HCV) infection and significantly increased sustained virologic response (SVR) rates over pegylated interferon alfa combined with ribavirin ( peg-IFN/RBV) alone. Telaprevir, a potent, selective HCV protease inhibitor, binds to the catalytic site of NS3/4A, thereby preventing processing of the nonstructural proteins necessary for viral RNA replication [1] [2] [3] [4] .
Telaprevir treatment leads to a rapid decrease in circulating plasma HCV RNA and exerts strong selective pressure on the viral population [5, 6] . Telaprevirresistant variants carrying amino acid changes in the NS3 protease were observed in a subset of patients who failed a telaprevir-containing regimen during clinical development [7, 8] . In the presence of telaprevir, these resistant variants have a selective advantage over wildtype (WT), drug-sensitive strains. Kieffer et al [8] report that in the NS3 protease region, variants V36A/ M, T54A/S, R155K/T, A156S/T, and D168N were enriched in the viral populations of those patients who did not achieve an SVR relative to treatment-naive patients across phase 2 and 3 clinical trials. All of these variants, except for D168N, result in a reduction in the replicon-derived inhibitory potential of telaprevir, as do the less frequently observed resistant variants V36G, R155G/M, and A156F/N/V. However, in the absence of the inhibitor, the relatively impaired fitness of strains carrying these variants suggests that they may be outcompeted by WT virus after drug-selective pressure is removed, with WT virus either outgrowing from a residual population of WT virus or being generated via de novo back-mutation to the WT state.
Evidence for this phenomenon has been provided from a small number of clinical studies. In a phase 1 study, 34 patients were dosed with telaprevir monotherapy for 2 weeks [9] . After the end of the dosing period, the majority of virus in the populations of each patient harbored resistance. After removal of the inhibitor that was driving the population to directionally select those resistant variants, the frequency of WT virus relative to the resistant virus increased markedly within 7-10 days of follow-up, to near elimination by the 3-to 7-month follow-up visit [10, 11] . A subset of these patients were combined with a subset of patients from another phase 1 trial of telaprevir to evaluate the long-term fate of these variants using a more sensitive ultra-deep pyrosequencing approach [12] . With a sensitivity of 0.05% minority variant detection, Thomas et al found the frequency of resistance at a 4-year follow-up visit to be virtually indistinguishable from baseline in 14 of 15 patients, with the remaining patient harboring approximately 5% resistance about 4 years after treatment [12] .
These previous studies suggest the potential for resistant variants to be outcompeted by WT virus, but there are 2 limitations that may limit the generalizability of the results: The studies had a small sample size, and the clinical trials utilized a short (2-week) duration of telaprevir. The objective of this retrospective analysis was to determine the prevalence of these resistant variants among patients who did not achieve SVR after the longer durations (8 or 12 weeks) of telaprevir tested in phase 3 clinical trials and to determine their clinical fitness after treatment. In this analysis, we pooled viral sequence data across all 3 of the telaprevir phase 3 clinical development studies, and included both treatment-naive and previously treated patients [13] [14] [15] . Our data suggest that resistant variants are present in most, but not all, patients directly after viral breakthrough or relapse, with those variants being more common in 1a than in 1b infections. Furthermore, over time after treatment failure, resistant variants are replaced by WT virus.
METHODS

Clinical Trial Protocols
ADVANCE [13] , ILLUMINATE [14] , and REALIZE [15] were phase 3 clinical studies that evaluated either 8-or 12-week telaprevir treatment durations (8-week telaprevir, ADVANCE) with either 24-or 48-week durations of peg-IFN/RBV (ADVANCE/ILLUMINATE); all REALIZE patients received a 48-week treatment. The enrolled patient population included both treatment-naive (ADVANCE, ILLUMINATE) and previously treated (REALIZE) patients, the latter of whom had not achieved SVR on a previous regimen of interferon and ribavirin. The enrolled study populations were chronically infected with genotype 1 HCV.
Studies were conducted in full compliance with the guidelines of Good Clinical Practice and of the World Medical Assembly Declaration of Helsinki. Prior to study initiation, protocols and informed consent forms were reviewed and approved by institutional review boards at each site. All patients provided written informed consent before participating in any study-related activity.
HCV RNA Assessment and Population Sequence Analysis
Plasma HCV RNA levels were determined using the Roche COBAS TaqMan HCV/HPS assay (version 2.0). The lower limit of quantification was 25 IU/mL and the limit of detection (LOD) was 10-15 IU/mL. After treatment failure, sequence of the NS3 protease region was determined as previously described [16] at time points where HCV RNA levels exceeded the population sequence analysis assay LOD (1000 IU/mL). The sensitivity of detection of minority variants using population sequencing is approximately 20%. In brief, the sequencing methodology employed reverse transcription of RNA isolated from patient plasma samples followed by nested polymerase chain reaction of an approximately 9-kb genomic fragment. Nucleotide sequence was determined by direct sequencing of amplicons (ie, viral population sequencing), and the NS3 protease was inferred from the nucleotide sequence, with 3× or greater coverage available for all nucleotide positions.
Statistical Analyses
Sequence data from the time at or immediately following treatment failure (eg, viral breakthrough or relapse) were considered to be representative of the viral population at the time of failure. For the purpose of survival analyses, the time of origin was defined as the first time point for which viral sequence data were available after the patient had viral rebound to an HCV RNA level ≥ 1000 IU/mL and telaprevir dosing had been completed or discontinued. Kaplan-Meier survival analyses were conducted in JMP (version 8.0.1) and independently confirmed using R (version 2.13.1). Wilcoxon tests were used to evaluate the hypothesis of homogeneity of compared groups. Overall, type 1 error was controlled at an α level of .05 using a Bonferroni correction, resulting in a .007 level for each of the 7 tests performed. All P values reported represent uncorrected P values and should be evaluated against the Bonferroni-corrected α value.
An initial survival analysis included all patients with sequence data after treatment failure (n = 388, Figure 1 ), with the "resistance loss event" assumed to occur at the first time point after failure where no resistance was detected and V36A/L/M/ G/I, T54A/S, I132V (1a only), R155G/K/M/T, A156F/N/S/T/V, and D168N were considered resistant variants [7] . Patients lacking detectable resistant variants at the first time point after failure were considered to have had the loss event at time zero. The definition of "resistance loss event" also necessitated that the virus had either the WT consensus amino acid at positions associated with resistance (ie, V36, T54, I132V [1a only], R155, A156, and D168) or had returned to the patient-specific baseline value for those positions. For example, if a patient possessed the R155K variant at the time after treatment failure and was R155R/Q at a subsequent time point, the patient would not have been considered to have had the resistance loss event even though R155Q is not published as a telaprevir-resistant variant.
To determine the timing of loss of specific resistant variants, patients with resistant variants prior to treatment (n = 26) were excluded from subsequent analyses exploring time to loss of a given resistant variant, as the viral populations in these patients may have had additional mutations making these variants more fit (hence their occurrence before treatment). Patients without any follow-up assessments after the initial identification of the resistant variant were also excluded from the analysis, as they were uninformative.
RESULTS
Patient Population and Resistance Frequency at Treatment Failure
A total of 1797 patients were treated with a telaprevir-based regimen in phase 3 clinical trials ( Figure 1 ). Viral population sequencing was performed at and after the time of treatment failure at visits with HCV RNA levels above the assay LOD (1000 IU/mL). Sequence data were available for 388 patients at treatment failure and were analyzed for the presence of resistant virus.
At treatment failure, 77% of patients (299/388) had detectable telaprevir-resistant variants (Table 1, Figure 1 ). Resistant variants were more common in subtype 1a-infected patients (86%, 232/269) than in subtype 1b-infected patients (56%, 67/ 119). Of the 299 patients with detectable resistant variants, 44% contained a single variant, 44% contained the V36M + R155K Figure 1 . Patient accounting diagram. Blue boxes on the left indicate the analyses performed. All patients with postfailure sequence data (n = 388) were used to explore the probability of resistance at failure and over time. Patients with resistance at failure and additional follow-up data (n = 254) were used to explore the loss of resistant variants. a The cause for a patient not having any postfailure sequencing data was defined hierarchically in the order of the bullets within the box. Seventy-one percent (n = 70) of the patients with viral loads <1000 IU/mL had undetectable hepatitis C virus RNA but were classified as non-sustained virologic response (SVR) for various reasons (eg, lost to follow-up at SVR assessment).
c Patients with a resistant variant at baseline were excluded from the "by variant" rate of loss analysis. Abbreviations: HCV, hepatitis C virus; SVR, sustained virologic response. 
Viral Populations and Resistance Evolution After Treatment Failure
An analysis of viral populations after treatment failure was performed to determine the probability of a patient having detectable resistance over time in the absence of study drug. All 388 patients with viral sequence data from 1 or more time points after treatment failure were included in this analysis. Of these patients, 91% (355/388) had follow-up viral sequence data from ≥1 visit after treatment failure, with an overall median number of 3 follow-up visits (range, 0-15; Figure 2A ) and an overall median follow-up time of 9.6 months (range, 0-16; Figure 2B ). At treatment failure, 254 patients had resistant variants and at least 1 follow-up visit (Figure 1 ). Of these 254 patients, 60% (153/254) no longer had detectable resistant variants by population sequencing. Of the remaining 101 patients who still had detectable resistance variants at their last visit, 15 had ≥1 year of follow-up sequence data ( Figure 3 ). All but 1 of these 15 patients had 2 resistant variants at the time of failure (R155K in "N" is number of patients with sequence data available at 1 or more visits after treatment failure; "n" is the number of patients lacking detectable resistant variants at end of study. All patients, including those with detectable resistant variants at baseline (1a, n = 22; 1b, n = 4), are included in the analysis. B and C, Loss of individual variants for subtypes 1a (B ) and 1b (C ). Only emergent variants (ie, those not present prior to treatment) are analyzed. "N" is the number of patients with a given variant at the time of treatment failure and at least 1 follow-up visit; "n" is the number of patients lacking the variant at end of study. KM analysis is limited to variants present in 3 or more patients. D, Time to loss of both V36M and R155K for those patients with double mutation compared with time to loss of either V36M or R155K for those patients with single mutation. Sample sizes can be derived from (E and F ). E and F, Loss of V36M or R155K by resistant variant multiplicity. Of those patients lacking a resistant variant detected at baseline and at least 1 follow-up visit after the treatment failure visit, 124 had the double mutation, 24 had V36M in the absence of R155K (F ), and 36 had R155K in the absence of V36M (E ). Censored observations are indicated by hash marks in all figures except (B ) and (C ), where spacing of the graphic precludes their clear representation.
combination with V36M or V36L), and by their last visit, 9 of these 15 patients had lost 1 of the 2 variants. Viral populations became WT significantly more rapidly for subtype 1b relative to subtype 1a (P < .0001, log-rank test; Figure 4A ). The estimated median time to WT for 1a patients was 10.6 months (95% confidence interval [CI], 9.47-12.20), in contrast to <1 month for 1b patients (95% CI, 0-2.07; Table 2 ; Figure 4A ). The most common 1b variants (V36A, T54A, A156S/T) had median times to loss of approximately 3-4 months, whereas the most common 1a variants (V36M, R155K) had median times to loss of approximately 10 months ( Table 2 ), suggesting that common 1b variants have relatively lower fitness than 1a variants (Figures 4B and C) .
Patients with the most common 1a resistance profile (V36M + R155K) took significantly longer to lose both variants than patients with V36M alone (P < .0001) and possibly longer than those with R155K alone (P = .01; Figure 4D ). The time to loss of R155K did not vary as a function of variant multiplicity (P = .80; Figure 4E ), with median times to loss of R155K of approximately 10 months regardless of whether the variant was present alone or with V36M. Although not statistically significant after adjustment for multiple testing, V36M may be retained longer when present as part of the V36M + R155K combination (P = .01; Figure 4F ), given a median time to loss of 6 months (95% CI, 4.0-9.3) when present by itself, compared with 10 months (95% CI, 8.1-11.1) when present as part of the V36M + R155K combination variant.
In addition to our assessments to determine the viral factors (ie, viral subtype, specific resistant variant) that determine the time to loss of resistant variants, we also explored if the host's ability to respond to peg-IFN/RBV impacted the time to loss of resistance. The REALIZE trial enrolled prior peg-IFN/RBV treatment failures, whereas the ADVANCE and ILLUMINATE studies enrolled peg-IFN/RBV treatment-naive patients. No differences were noted in the time to WT between treatmentnaive and prior treatment-experienced patients ( Figure 5 ).
DISCUSSION
In this pooled retrospective analysis, we analyzed a large (N = 388) study population of patients who did not achieve SVR with telaprevir treatment to explore the frequency of resistance and to further explore the evolution of these viral populations thereafter. Our findings indicate that resistant variants tend to resolve to WT after treatment failure: Whereas 77% of patients with any sequence data possessed resistant variants immediately after failure, 60% of patients with variants and sequence data from 1 or more follow-up visits lost those variants (median available follow-up was 9.6 months for all patients with sequence data from 1 or more follow-up visit). The probability of a patient having detectable resistance did not appear to be associated with prior peg-IFN/RBV treatment status ( Figure 5 ), but did appear to be associated with the viral subtype ( Figure 4A ): Common 1b variants are lost significantly more rapidly than common 1a variants. After treatment failure, the median time to WT is approximately 1 month for 1b and approximately 11 months for 1a. e Note that because this analysis includes those patients with only WT virus at treatment failure, the estimates are lower than the time to loss of known resistant variants. f For the "by resistant variant" analysis, only patients with only WT virus prior to treatment and had resistant variants at the time of failure are included. If a patient had more than 1 resistant variant, the patient may contribute data to more than 1 row. Time-to-event analyses estimate the interval from the time of failure visit to the time at which a given variant is no longer detectable by population sequencing; "n" indicates the number of patients that have a resistant variant observed at treatment failure with at least 1 additional followup visit allowing evaluation of persistence of resistant variants. g This variant was observed in only a single 1a patient; the "median" estimate represents the data for this patient only. h This variant was observed in two 1b patients, only 1 of whom retained the variant.
The longer time to loss in subtype 1a may be explained by the subtype-specific suite of resistant variants present after treatment failure and the relatively higher fitness of the variants commonly associated with this subtype, notably R155K. After treatment failure, V36M and R155K were the most common resistance profile in patients with subtype 1a infections, present either individually or in combination. Notably, the variant R155K was never observed in patients with subtype 1b in this study, and V36M was rare in this subtype relative to the more commonly occurring variants V36A, T54A, and A156S/T. Our data suggest that the variants that occur more commonly in subtype 1b have poorer fitness than variants V36M and R155K (Table 2 ; Figure 4B and C). Interestingly, the co-occurrence of V36M and R155K ( presumably on the same genomic backbone) appears to be more fit than the V36M variant when present by itself ( Figure 4F ), but does not appear to improve the fitness of the R155K variant ( Figure 4E ).
The subtype-specific patterns have been explained as resulting from a differential intrinsic genetic barrier driven by different codon biases [11, 17] . In the case of subtype 1a, both V36M and R155K can be generated via a single transition mutation from the common codon at each of these positions. By contrast, each of these amino acid changes requires 2 mutations in the most common 1b codons, and notably, 2 of these 4 changes are transversions. Notably, while V36M was observed in 2 subtype 1b patients in this study, R155K was not observed in this subtype despite the theoretical potential for its evolution. The 1b variants that therefore occur most commonly after treatment failure result in less-fit variants. These less-fit variants are also observed occasionally in subtype 1a, where they tend to be rapidly replaced with WT virus (Figure 4B ), which is consistent with the interpretation that the apparent differential fitness between 1a and 1b is a function of the differential fitness of the specific resistant variants rather than the HCV subtype.
The more rapid rate of loss of 1b variants suggests a hypothesis for the observation that resistance is more common after treatment failure in 1a patients (86%) than 1b patients (56%). Because of infrequent sampling during follow-up and the fact that the HCV RNA concentration must be ≥1000 IU/mL for successful amplification, there is a delay between the initiation of viral rebound and time of sequencing. It is likely that resistant variants were present as a large fraction of the viral population at treatment failure in most patients. However, by the time the viral sequencing assessment was performed, the WT virus may have already outcompeted the resistant viral populations in those patients identified as having WT virus at failure. Because the variants V36M and R155K are more fit than the common 1b variants, a longer time is required for WT virus to outcompete these resistance variants, and therefore, a larger fraction of 1a-infected patients still have resistant variants present at the first assessment after failure.
In these analyses, the observed viral fitness is determined by the retention of resistant variants after the end of treatment, which may be affected by a number of factors. In patients who discontinue treatment before the viral population has purified to a resistant state, the remaining WT virus in the population might be expected to rapidly outcompete resistant variants. In addition to the fraction of WT virus that may still be remaining at the end of treatment or during follow-up, viral fitness will also be affected by the genetic barrier of reversion to WT (ie, the number of nucleotide changes required for de novo reversion) and the absolute replicative capacity of the variant. Therefore, a variant may be retained longer in a population than a more intrinsically fit virus if the former variant has a larger genetic barrier for reversion.
Overall, these data suggest that resistant variants present at treatment failure will be replaced with WT within approximately 16 months in most patients. Two possible mechanisms for this are WT virus reemerging from small residual populations or WT being generated by de novo back-mutation. Other viral diseases, such as human immunodeficiency virus and hepatitis B virus, have archiving mechanisms, such as long-lasting Figure 5 . Kaplan-Meier estimates of loss of telaprevir-resistant variants over time, by prior pegylated interferon plus ribavirin treatment status. The ADVANCE and ILLUMINATE studies are pooled in the treatment-naive group. All patients from REALIZE are included in the treatment-experienced group. There is no significant difference between treatment-experienced and -naive patients in the retention of resistant variants (Wilcoxon test: 1a, P = .28; 1b, P = .22). Abbreviation: CI, confidence interval.
nuclear DNA forms, which enable resistant variants to reemerge rapidly upon exposure to a similar selective pressure. In contrast, HCV is not likely to have an archiving mechanism, as replication occurs entirely as RNA and within the cytoplasm, suggesting that the levels of resistant virus in HCV populations could return to baseline levels in the absence of the inhibitor. Although this study did not include more sensitive sequencing techniques, other studies utilizing massively parallel or clonal sequencing techniques have quantitatively demonstrated that levels of resistant virus are comparable at baseline and approximately 1-4 years after administration of a telaprevir-based regimen [12] . Although retreatment trials will be necessary to fully understand the clinical significance of these observations, taken together, these data suggest that telaprevir or other protease inhibitors may potentially be an effective component of future multiple direct-acting antiviral regimens for patients who did not achieve SVR with a protease inhibitor-containing regimen.
Notes
